Reunion Neuroscience Inc. - REUN STOCK NEWS

Reunion Neuroscience (NASDAQ: REUN) reported significant business advancements in its press release dated November 14, 2022. The company completed dosing for the Phase 1 trial of its lead drug candidate, RE104, which aims to address postpartum depression. With cash reserves of CAD 36.7 million as of September 30, 2022, Reunion is positioned for future growth. The appointment of experienced leadership, including Greg Mayes as CEO, is set to enhance strategic direction. The company also initiated preclinical work on its RE200 series, promising further innovation in mental health therapeutics.

Reunion Neuroscience Inc. (NASDAQ: REUN) will release its fiscal 2023 Q2 business update and financial results on November 14, 2022, before market open. A conference call will follow at 8:30 a.m. ET, accessible via phone or webcast. Reunion, previously known as Field Trip Health Ltd., focuses on innovative treatments for mental health issues, particularly postpartum depression with its lead asset RE104, a novel serotonergic psychedelic compound, which has received a patent until 2041.

Reunion Neuroscience Inc. (NASDAQ: REUN) announced its participation in two major conferences this November. The first event is the Hanson Wade 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit, where CEO Greg Mayes will moderate discussions on development strategies and hallucination impacts on efficacy on November 1. The second event is the Jefferies London Healthcare Conference on November 16, featuring presentations by leadership, including Mayes and Chief Scientific Officer Nathan Bryson. A webcast of the presentation will be available on their website.

Reunion Neuroscience Inc. has appointed Edward Smith as CFO and Aviva Asnis-Alibozek as VP of Medical Affairs, enhancing its executive team amidst advancing clinical trials. Smith brings over 20 years of experience, having raised $600 million in previous roles. Asnis-Alibozek, a Yale graduate, has a strong background in medical affairs. Their expertise is expected to strengthen Reunion's position in developing treatments for mental health disorders, particularly as it prepares for a Phase 2 study in postpartum depression. Former CFO Donna Wong will remain as Corporate Secretary for a transitional period.

Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) is set to participate in the Horizons Perspectives on Psychedelics conference on October 13, 2022, focusing on capital raising in the psychedelic medicine sector. President and CEO Greg Mayes will discuss the urgent need for innovative treatments in mental health, emphasizing the potential of psychedelic therapies. The panel titled “Raising Capital for Psychedelic Endeavors” aims to explore how companies are securing funding in this emerging field. This conference is the largest annual gathering for the psychedelic community.

Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) announced the resignation of Ronan Levy as Director and Paula Amy Hewitt as General Counsel, effective October 7, 2022. The Company appointed Greg Mayes, CEO, as Director and Donna Wong, CFO, as Corporate Secretary. Reunion focuses on developing serotonin receptor agonist compounds for mental health, with its lead asset, RE-104, targeting treatment-resistant depression. The company aims to innovate fast-acting antidepressant solutions.

On October 3, 2022, Reunion Neuroscience (TSX: REUN, Nasdaq: REUN) announced its participation in the Cantor Neurology & Psychiatry Conference scheduled for October 6-7, 2022, at the Ritz Carlton, San Francisco. The management team will present on the panel titled “Tripping Our Way to a New Treatment Paradigm for Psychiatric Disorders” on October 6 at 12:10 PM PT. Additionally, they will conduct one-on-one meetings with institutional investors. Reunion focuses on the development of innovative psychedelic therapies, including its lead asset, RE-104, aimed at treating post-partum and treatment-resistant depression.

Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) held its Annual General and Special Meeting on September 29, 2022, with 5,073,132 shares represented, equating to 43.57% of outstanding common shares. All proposed matters were approved by a majority vote, including the election of directors and reappointment of Ernst & Young LLP as auditors. Results showed strong support for nominees, with the highest percentage of votes for being 99.92%. Additionally, shareholders adopted the second amended equity incentive plan, reflecting overall positive engagement from the shareholder base.

Reunion Neuroscience Inc. has appointed Greg Mayes as President and Chief Executive Officer, succeeding Joseph del Moral, who will become Chairman. Mayes brings over 20 years of biopharma industry experience, having previously led significant fundraising efforts and clinical trials at various biotech firms. His focus will be on completing the Phase 1 clinical trial of RE-104 and launching its Phase 2 study targeting postpartum depression in 2023. Mayes aims to develop innovative serotonergic psychedelic therapies that could address the mental health crisis impacting millions globally.